COVAXIN
What can India learn from its response to the pandemic?

It has been one year since the Narendra Modi government in India imposed a nationwide lockdown in response to the COVID-19 pandemic.

MSF reports civilians killed by Ethiopian soldiers in Tigray and other stories

Today we take a look at recent reports of the killing of civilians in the Tigray region, custodial deaths of Indigenous people in Australia, police repression against a protest in Jordan, and the key lessons learned as India marks 1 year of the Covid-19 lockdown

Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.

In India, pseudo-nationalism trumps science in vaccine clearance

The recent regulatory clearance given to an indigenous developed vaccine candidate in India is an example of vaccine nationalism at its worst and jettisoning of all the principles of an evidence-based, scientific approach

COVID-19 Vaccines: Moderna declares successful trial results after Pfizer

The new vaccine candidate by Moderna Inc, called mRNA-1273, has reportedly shown 94.5% efficacy against the SARS-CoV-2 in the phase III clinical trials

    × To Subscribe